Filing Flows › Sutro Biopharma (STRO) › Stock forecast & fair value
Sutro Biopharma (STRO) stock forecast and price target
Sutro Biopharma (STRO) trades at $9.62. 13 analysts' median price target is $50.00 (+420%), from $10.00 to $61.00.
Sutro Biopharma's latest quarter
Sutro Biopharma, Q2 2026: revenue $9.8M (-85% year over year), operating margin -303.8%, net loss $38.5M, operating cash flow −$38.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for STRO stock?
The median of 13 analysts' 12-month targets is $50.00, +420% from $9.62; the range is $10.00 to $61.00. The average rating is strong buy.
Does Sutro Biopharma usually beat earnings estimates?
It beat the consensus EPS estimate in 25% of the quarters on record.
Is STRO stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.